Basic Neurosciences · Paper A
Neurotransmitter metabolites
Each brain signalling chemical (neurotransmitterA chemical messenger that nerve cells release to signal to the next cell.Read more →) is broken down into a specific waste product, and measuring that product in blood, urine or spinal fluid gives a clue to how active that transmitter system has been. For example, imagine measuring a patient's cerebrospinal fluid and finding an unusually low level of one specific breakdown product. In practice, that single low result has been linked to a specific behavioural risk, not just a lab curiosity.
Serotonin (5-HT) breaks down to 5-HIAA. Dopamine breaks down to homovanillic acid (HVA). Noradrenaline breaks down to MHPG (and VMA). Adrenaline and noradrenaline together also break down peripherally to VMA, which is used to screen for phaeochromocytoma (an adrenaline-producing tumour). Low cerebrospinal fluid 5-HIAA is linked with impulsivity, aggression and suicide risk. For example, imagine a research study measuring 5-HIAA in a group of patients with a history of impulsive violence, a lower average 5-HIAA in that group is the classic finding behind this association. In practice, this means the 5-HIAA-impulsivity link is treated as one biological marker among several, never as a stand-alone diagnostic test.
A is a brain signalling chemical released by one neuron to communicate with the next. It matters practically because you cannot easily sample a living brain's directly, but you can measure what the body leaves behind after using a transmitter, and that indirect trail is exactly what a metabolite gives you.
After a has done its job, the body breaks it down into a metabolite (a smaller, inactive breakdown product) so the signal does not linger indefinitely. Measuring that metabolite in blood, urine, or cerebrospinal fluid (CSF, the fluid bathing the brain and spinal cord, sampled by lumbar puncture) gives an indirect readout of how active that transmitter system has been.
A metabolite level is best understood as a proxy for turnover (the rate at which a transmitter is being synthesised, released, and broken down), not a direct measure of transmitter concentration at the at any single moment. A static blood or urine sample cannot show minute-to-minute synaptic activity; it can only show the accumulated downstream signature of activity over hours. Forgetting this caveat is what leads people to over-interpret a single metabolite value as if it were a precise real-time brain reading.
Imagine a laboratory report listing three separate metabolite values for one patient; each value maps back to exactly one parent transmitter, so reading the report correctly means knowing the pairings by heart. Serotonin (5-hydroxytryptamine, 5-HT), the transmitter most linked to mood regulation, breaks down to 5-hydroxyindoleacetic acid (5-HIAA). Dopamine, central to reward, motivation, and movement, breaks down to homovanillic acid (HVA). Noradrenaline, involved in arousal and the stress response, breaks down mainly to MHPG (3-methoxy-4-hydroxyphenylglycol), with some contribution to vanillylmandelic acid (VMA) as well. Adrenaline and noradrenaline together also break down peripherally, outside the brain, to VMA, and that peripheral pathway is the one exploited clinically.
Two diagnostic uses stand out. First, low 5-HIAA has been consistently linked, across multiple research studies, with impulsivity, aggression, and suicide risk; a lower average 5-HIAA is the classic finding in groups of patients with a history of impulsive violence. This is treated as one biological marker among several contributing to a risk assessment (a structured judgement of a patient's likely future risk), never as a stand-alone diagnostic test on its own, since many people with low 5-HIAA never act violently. Second, VMA measured in a 24-hour urine collection is used as a screening investigation for phaeochromocytoma, a rare adrenaline-producing tumour of the adrenal gland, in patients presenting with episodic high blood pressure, palpitations, headache, and sweating.
The commonest exam trap is confusing which tumour goes with which metabolite. Phaeochromocytoma (raised catecholamines) is screened for with urinary VMA, and presents with episodic hypertension, palpitations, headache, and sweating. Carcinoid syndrome, by contrast, a tumour releasing excess serotonin, is screened for using raised urinary 5-HIAA rather than VMA, and presents with flushing, diarrhoea, and wheeze rather than hypertensive spells. A raised HVA points toward dopamine-secreting tumours such as neuroblastoma in children, a completely different clinical picture again. Diet and medication can also mimic a true abnormal result: certain foods (such as bananas and walnuts) and monoamine-oxidase inhibitor drugs can raise VMA or HVA independent of any underlying tumour, so a raised metabolite in isolation is not the same as a confirmed tumour diagnosis.
Diagnosis proceeds by working backwards from the clinical scenario, deciding which transmitter system is implicated, and only then selecting the correct metabolite test, rather than ordering every metabolite at once. Suppose a question describes a patient with sudden, severe hypertensive episodes and flushing: the transmitter system implicated is catecholamine (adrenaline/noradrenaline), so the correct test is urinary VMA, not 5-HIAA or HVA. sampling, obtained by lumbar puncture, is invasive and used mainly in research settings or specialist investigation, whereas urinary VMA or 5-HIAA collection is the routine, practical screening tool used in everyday endocrinology because it is non-invasive. A clinician should always ask about diet and current medication before ordering or interpreting these tests, and repeat testing or confirmatory imaging (CT or MRI of the adrenal glands) is standard practice before any irreversible management step such as tumour surgery is planned.
Management decisions follow directly from correctly matching the metabolite to its transmitter and its clinical context. A confirmed phaeochromocytoma is managed first with alpha-blockade (drugs such as phenoxybenzamine) to control blood pressure safely, followed by beta-blockade if needed, before surgical removal of the tumour; guidance from endocrine surgery and WHO tumour classification standards underpins this stepwise approach. A patient with low 5-HIAA and a history of impulsive, aggressive behaviour is not treated on the basis of that laboratory value alone; instead, management follows the clinical picture, which may include psychological therapy, risk-reduction planning, and in some cases pharmacological treatment such as an (selective serotonin reuptake inhibitor), used first-line per Maudsley Prescribing Guidelines and NICE recommendations for related mood and impulse-control presentations.
A reliable trick under exam pressure is to anchor each metabolite to its clinical presentation rather than its chemistry: hypertensive spells and flushing means VMA (catecholamines/phaeochromocytoma), while flushing with diarrhoea and wheeze means 5-HIAA (serotonin/carcinoid): the overlapping word "flushing" is exactly the trap designed to make you pick the wrong metabolite.
A metabolite is an indirect proxy for transmitter turnover, not a real-time brain reading, and matching the right metabolite (5-HIAA, HVA, or VMA) to the right clinical picture is the entire skill being tested.